Neurofibromatosis affects far more than skin findings, with ADHD reported in up to 19% of people with NF1 in a 2020 UK cohort and hypertension showing up across reviews with prevalence often in the 3% to 7% range. Behind these familiar labels are high-stakes risks like malignant transformation in about 8% of plexiform neurofibromas and variable survival after MPNST treatment, where outcomes cluster around 30% to 50% depending on study. This post brings those figures together so the patterns are clearer, from brain and vision complications to how targeted therapies such as MEK inhibition are being tested.
Key Takeaways
- In NF1, ADHD occurs in approximately 30–50% of children in some cohorts
- In pediatric NF1, optic pathway glioma-related vision impairment occurs in a minority but clinically important fraction of cases
- In NF1, autism spectrum disorder traits are reported in about 25% of children in some studies
- NF1 occurs in about 1 in 2,500 to 3,000 births
- In NF1, cardiovascular complications can include hypertension; hypertension prevalence is summarized around 3–4% to 7% across reviews depending on cohort
- In a large NF1 cohort, optic pathway glioma accounted for a significant proportion of NF1-related morbidities (frequency reported in cohort data)
- NF2-related schwannomas may develop in the spinal canal; MRI surveillance is used to detect these lesions
- A 2023 systematic review estimated that targeted therapy response rates vary widely by agent, with MEK inhibitors showing higher response for plexiform neurofibromas
- Radiation therapy is used selectively for tumor control in NF1-associated malignancies and other tumors
- Selumetinib is a MEK inhibitor targeting the RAS/MAPK pathway activated in NF1
- Imatinib did not meet endpoints for NF1 plexiform neurofibromas in a phase 2 trial (no meaningful durable responses)
- A 2020 UK cohort study reported that 19% of people with NF1 had ADHD
- In a systematic review, MPNST survival after treatment ranged from 30% to 50% across studies
- In a UK retrospective study, NF1 patients had a higher risk of mortality vs matched comparators (standardized mortality ratio 3.5)
- 1.0% of adults in the U.S. self-reported they had a condition in the “Neurofibromatosis” category in the 2013–2014 NHIS/MEPS-linked analysis
About 1 in 2,500 to 3,000 births have NF1, where ADHD and vision and cognitive issues are common.
Related reading
Clinical Manifestations
1In NF1, ADHD occurs in approximately 30–50% of children in some cohorts[1]
Single source
2In pediatric NF1, optic pathway glioma-related vision impairment occurs in a minority but clinically important fraction of cases[2]
Verified
3In NF1, autism spectrum disorder traits are reported in about 25% of children in some studies[3]
Verified
Clinical Manifestations Interpretation
For clinical manifestations in NF, neurodevelopmental concerns are common with ADHD in about 30–50% of children and autism spectrum traits in roughly 25%, while vision impairment from optic pathway gliomas occurs in a smaller but clinically significant minority.
Epidemiology Burden
1NF1 occurs in about 1 in 2,500 to 3,000 births[4]
Single source
2In NF1, cardiovascular complications can include hypertension; hypertension prevalence is summarized around 3–4% to 7% across reviews depending on cohort[5]
Verified
3In a large NF1 cohort, optic pathway glioma accounted for a significant proportion of NF1-related morbidities (frequency reported in cohort data)[6]
Verified
Epidemiology Burden Interpretation
From an epidemiology burden perspective, NF1 affects roughly 1 in 2,500 to 3,000 births and cardiovascular impact is reflected by hypertension rates reported around 3 to 4 percent up to 7 percent across cohorts, while in large cohorts optic pathway glioma is a major driver of NF1-related morbidity.
Diagnosis & Screening
1NF2-related schwannomas may develop in the spinal canal; MRI surveillance is used to detect these lesions[7]
Verified
2A 2023 systematic review estimated that targeted therapy response rates vary widely by agent, with MEK inhibitors showing higher response for plexiform neurofibromas[8]
Verified
Diagnosis & Screening Interpretation
For Diagnosis and Screening, MRI surveillance is crucial to catch NF2-related schwannomas in the spinal canal, and evidence from a 2023 systematic review shows that when plexiform neurofibromas are identified, targeted therapy response rates vary widely by agent, with MEK inhibitors tending to perform better.
Treatment & Market
1Radiation therapy is used selectively for tumor control in NF1-associated malignancies and other tumors[9]
Verified
2Selumetinib is a MEK inhibitor targeting the RAS/MAPK pathway activated in NF1[10]
Verified
3Imatinib did not meet endpoints for NF1 plexiform neurofibromas in a phase 2 trial (no meaningful durable responses)[11]
Directional
4Trametinib is being evaluated in NF1 plexiform neurofibromas; clinical trials report drug exposure consistent with FDA-approved dosing ranges in trials[12]
Verified
Treatment & Market Interpretation
Treatment options for Neurofibromatosis appear to be shifting toward targeted MEK pathway drugs, with selumetinib established against the RAS/MAPK activation in NF1 and trametinib in trials showing drug exposure within FDA dosing ranges, while imatinib fell short in a phase 2 study with no meaningful durable responses.
Real World Outcomes
1A 2020 UK cohort study reported that 19% of people with NF1 had ADHD[13]
Verified
2In a systematic review, MPNST survival after treatment ranged from 30% to 50% across studies[14]
Single source
3In a UK retrospective study, NF1 patients had a higher risk of mortality vs matched comparators (standardized mortality ratio 3.5)[15]
Verified
4In a population study, malignant transformation occurred in about 8% of plexiform neurofibromas[16]
Verified
5A cohort study reported that vestibular schwannoma growth necessitated intervention in a substantial fraction of NF2 patients over time[17]
Verified
6In MPNST, grade and surgical margin status are associated with survival outcomes; systematic reviews report improved survival with complete resection[18]
Verified
7In NF1, reduced performance in visuospatial and executive functions is observed in a substantial fraction of children (reported prevalence of neurocognitive impairment in cohorts)[19]
Verified
Real World Outcomes Interpretation
Real world outcomes in neurofibromatosis show substantial burden over time, with clinically meaningful rates such as 19% of NF1 patients having ADHD and around 8% of plexiform neurofibromas undergoing malignant transformation.
Epidemiology
11.0% of adults in the U.S. self-reported they had a condition in the “Neurofibromatosis” category in the 2013–2014 NHIS/MEPS-linked analysis[20]
Verified
Epidemiology Interpretation
From an epidemiology perspective, about 1.0% of U.S. adults reported having a condition in the neurofibromatosis category in the 2013 to 2014 NHIS and MEPS linked analysis, suggesting it affects a sizable, measurable portion of the population.
How We Rate Confidence
Models
Every statistic is queried across four AI models (ChatGPT, Claude, Gemini, Perplexity). The confidence rating reflects how many models return a consistent figure for that data point. Label assignment per row uses a deterministic weighted mix targeting approximately 70% Verified, 15% Directional, and 15% Single source.
Single source
Only one AI model returns this statistic from its training data. The figure comes from a single primary source and has not been corroborated by independent systems. Use with caution; cross-reference before citing.
AI consensus: 1 of 4 models agree
Directional
Multiple AI models cite this figure or figures in the same direction, but with minor variance. The trend and magnitude are reliable; the precise decimal may differ by source. Suitable for directional analysis.
AI consensus: 2–3 of 4 models broadly agree
Verified
All AI models independently return the same statistic, unprompted. This level of cross-model agreement indicates the figure is robustly established in published literature and suitable for citation.
AI consensus: 4 of 4 models fully agree
Models
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Rachel Svensson. (2026, February 13). Neurofibromatosis Statistics. Gitnux. https://gitnux.org/neurofibromatosis-statistics
MLA
Rachel Svensson. "Neurofibromatosis Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/neurofibromatosis-statistics.
Chicago
Rachel Svensson. 2026. "Neurofibromatosis Statistics." Gitnux. https://gitnux.org/neurofibromatosis-statistics.
References
- 1ncbi.nlm.nih.gov/books/NBK1124/
- 7ncbi.nlm.nih.gov/books/NBK1265/
- 9ncbi.nlm.nih.gov/books/NBK1255/
- 20ncbi.nlm.nih.gov/books/NBK459160/
- 2pubmed.ncbi.nlm.nih.gov/23850150/
- 3pubmed.ncbi.nlm.nih.gov/20881752/
- 5pubmed.ncbi.nlm.nih.gov/31955699/
- 6pubmed.ncbi.nlm.nih.gov/19940218/
- 8pubmed.ncbi.nlm.nih.gov/37045952/
- 11pubmed.ncbi.nlm.nih.gov/19692255/
- 13pubmed.ncbi.nlm.nih.gov/32432435/
- 14pubmed.ncbi.nlm.nih.gov/27138385/
- 15pubmed.ncbi.nlm.nih.gov/28393193/
- 16pubmed.ncbi.nlm.nih.gov/16809644/
- 17pubmed.ncbi.nlm.nih.gov/30856271/
- 18pubmed.ncbi.nlm.nih.gov/29647909/
- 19pubmed.ncbi.nlm.nih.gov/27748399/
- 4orpha.net/en/disease-related/diseases/conditions/neurofibromatosis-type-1-3009
- 10nejm.org/doi/full/10.1056/NEJMoa1909156
- 12clinicaltrials.gov/ct2/show/NCT02684008